Skip to main content

Georgia’s First Talcum Ovarian Cancer Trial Is Set To Begin

Georgia’s First Talcum Ovarian Cancer Trial Is Set To Begin

Georgia’s First Talcum Ovarian Cancer Trial Is Set To Begin

Introduction

On Monday, September 9, the trial over claims that Johnson & Johnson’s (J&J) talc-based baby powder that caused ovarian cancer to a woman is set to begin in Atlanta. In the first case of its kind, Georgia jurors will have a chance to find a link between talcum powder and ovarian cancer.

A trial before Judge Jane Morrison involves the lawsuit filed by an Atlanta resident who died of ovarian cancer in 2016 at the age of 65. The woman filed a lawsuit against J&J shortly before her death. Her adopted minor granddaughter is the named plaintiff in this case.

Georgia jury will see evidence on how the use of talcum powder products for feminine hygiene can result in ovarian cancer. The trial is expected to continue for two weeks. As of February 2016, in seven different trials in Missouri and California juries have awarded more than $5.3 billion in damages against J&J.

From decades, studies have examined the link between genital talc use and ovarian cancer. The research shows that talc particles can migrate into the ovaries, causing inflammation and leading to the growth of malignant cells resulting in ovarian cancer. 

Talcum powder allegations include that the company knew about the risks of using talcum powder for decades and failed to warn the public of the potential risk of ovarian cancer in women despite numerous scientific studies suggesting talc as a cancer-causing mineral. Rather, they chose to market the talcum powder products to women and children for hygienic use despite being aware of the risks desiring profits before consumer safety. Lawsuits also claim J&J hid the fact that talcum powder contains asbestos.

Talc defendants currently face nearly 14,000 Talcum Powder and Shower-to-Shower lawsuits, consolidated under multidistrict litigation (MDL No. 2738; In Re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation), in the District of New Jersey. The MDL is presided by Hon. Freda L. Wolfson, U.S.D.J., and Hon. Lois H. Goodman, U.S.M.J.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Walgreens Settles Federal Opioid Case for $300 Million

Categories: Opioids

Walgreens has agreed to pay $300 million to settle allegations by U.S. prosecutors that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances.

The U.S. Department of Justice announced on Monday…

Study: Opioid Use in Pregnancy May Shrink Newborn Brains

Categories: Opioids

New research from Children’s National Hospital in Washington, D.C., reveals that infants exposed to opioids in the womb have significantly smaller brain volumes than…

Suboxone Tooth Loss Lawsuits Reviewed at MDL Meeting

Categories: Opioids

The U.S. District Judge overseeing the federal Suboxone tooth decay multidistrict litigation (MDL) is scheduled to meet with attorneys tomorrow to assess the progress of pretrial proceedings and strategize on resolving over 11,000 product…

🛠️ You Have Unfinished Work. We’ll Finish It — Free Trial.            
Free Trial + 25% Off All DLs & Med Review Case Backlog!

Only 12 Firms Can Join – First Come, First Served